CureVacCVAC
About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Employees: 1,100
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
12% more call options, than puts
Call options by funds: $322K | Put options by funds: $288K
1.46% less ownership
Funds ownership: 4.97% [Q3] → 3.5% (-1.46%) [Q4]
6% less funds holding
Funds holding: 80 [Q3] → 75 (-5) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
19% less capital invested
Capital invested by funds: $32.8M [Q3] → $26.6M (-$6.19M) [Q4]
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JMP Securities Roy Buchanan 24% 1-year accuracy 6 / 25 met price target | 459%upside $16 | Market Outperform Reiterated | 14 Feb 2025 |
Financial journalist opinion
Based on 4 articles about CVAC published over the past 30 days









